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LO-C.05 DEFINING THE INFLUENCE OF
GENDER DISCORDANCE ON SURVIVAL
FOLLOWING LIVING DONOR LIVER
TRANSPLANTATION
J. T. Miura, A. Fathi, F. M. Johnston, S. Tsai,
K. K. Christians, K. K. Turaga, T. C. Gamblin
Medical College Of Wisconsin, Department Of Surgery,
Milwaukee, WI
Background: Donor-recipient gender discordance has been
suggested to be an independent predictor of poor outcomes
following deceased donor liver transplantation (DDLT).
Whether a similar trend occurs with living donor transplants
(LDLT) remains ill defined. The present study sought to
evaluate the association between gender mismatch and sur-
vival following LDLT.
Study Design: Patients that underwent LDLT were identi-
fied from the Organ Procurement and Transplant Network
database (2000–2012), and categorized by the following
donor-recipient gender groups: Female (F)/F, Male (M)/F,
M/M, and F/M. Log rank test and multivariable Cox propor-
tional hazards models were used to assess graft survival (GS)
and overall survival (OS) of the study groups.
Results: A total of 3,143 LDLT were identified: 731 F/F,
794 M/F, 1,015 M/M, and 603 F/M. Ten year GS and OS
were highest in the F/F group, at 62% and 71% respectively,
as compared to M/F (53%, 66%), M/M (55%,62%), and F/M
(55%,66%). Multivariate analysis demonstrated that gender
mismatch was not associated with poorer GS (MM: Refer-
ence; MF: HR 1.22, p = 0.06; FF: HR 1.02, p = 0.86; FM:
HR 1.18, p = 0.18). Independent factors associated with
poorer GS included older recipient age (HR: 1.01, 95% CI:
1.00–1.02; p = 0.01), increasing donor age (HR: 1.01,
95%CI: 1.00–1.02; p = 0.01), higher Model for End-stage
Liver Disease score (HR: 1.02, 95%CI: 1.01–1.04;
p = 0.003), and left lobe allografts (HR: 2.08, 95%CI: 1.55–
2.79; p < 0.001).
Conclusions: Donor-recipient gender discordance does not
impact both GS and OS following LDLT. Living donor organ
allocation in an era of supply limitation should not be influ-
enced by donor gender.
LO-C.06 RECCURRENT
HEPATOCELLULAR CANCER AFTER
LIVER TRANSPLANTION: THE ROLE OF
LIVER-DIRECTED THERAPY
V. Donchev, G. Voidonikolas, M. Sheckley, A. Annamalai,
I. Kim, A. Klein, A. Wachsman, M. Friedman,
S. Colquhoun, N. Nissen
Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: Recurrence of hepatocellular cancer (HCC)
after liver transplant (LT) generally carries a poor prognosis.
We reviewed our experience to determine the role of liver-
directed treatments.
Methods: Retrospective review of 10-year single center
experience. All patients were within radiographic Milan cri-
teria for HCC at the time of LT. Of 201 patients undergoing
LT for HCC, 29 (14%) were identified with HCC recurrence.
Results: Mean and median time to recurrence after LT was
24 +/− 4 mo. and 15 mo. (range 3–160 mo.) respectively.
Explant pathology showed that most patients (26/29) had
pathologic staging exceeding Milan criteria. The initial
recurrence was liver-only in 7 patients (24%), liver-dominant
in 5 patients (17%) and systemic in 17 patients (59%). Time
to recurrence was greatest in the liver-only group at mean
34 mo., followed by mean 24 mo. in the liver-dominant
group and mean 14 mo. in systemic group. Patients with
liver-only or liver-dominant tumor underwent a total of 57
loco-regional treatments (range 1–14). There were 3 signifi-
cant treatment-related complications.
Survival: Mean survival after tumor recurrence in all
patients was 15 +/− 4 mo. The 1 and 3 year survival after
recurrence was 62% and 21% respectively. Patients undergo-
ing liver-directed therapy had improved survival compared to
the remainder of patients (25 mo. vs 14 mo., p < .05, figure).
Conclusions: HCC recurrence after LT is heterogeneous.
Almost all recurrences are in patients with poor explant
pathology. Aggressive liver-directed therapies are safe and
effective in patients with liver-dominant recurrence and can
lead to improved survival.
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LO-D.01 IMPROVED PERIOPERATIVE
OUTCOMES WITH EPIDURAL
ANALGESIA IN PATIENTS
UNDERGOING PANCREATECTOMY:
A NATIONWIDE ANALYSIS
D. E. Sanford, W. G. Hawkins, R. C. Fields
Washington University, St. Louis, MISSOURI
Background: Despite scant evidence demonstrating benefit,
epidural analgesia (EA) is often used for patients under-
going pancreatectomy. We sought to examine the impact
of epidural analgesia on postoperative outcomes after
pancreatectomy.
Methods: We used the 2008–2011 Healthcare Cost and Uti-
lization Project Nationwide Inpatient Sample to examine the
effect of EA on perioperative outcomes. Student’s t tests and
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chi-square tests were used for univariate comparisons.
Multivariable logistic and linear regression with propensity
score matching were utilized for risk-adjusted comparisons.
Results: 12,440 patients underwent pancreatectomy. Of
these, 1,130 (9.1%) patients received epidural analgesia.
Patients who received EA were significantly more likely to
be male, undergo pancreaticoduodenectomy, have cancer,
and undergo surgery at higher volume centers. By univariate
comparison, patients who received EA had significantly
lower rates of pneumonia, blood transfusions, and acute renal
failure, and this was associated with decreased postoperative
length of stay (LOS), lower hospital charges, and decreased
postoperative mortality. In multivariate analyses, EA was
independently associated with decreased postoperative LOS
(adjusted mean difference = −1.2 days, p < 0.01), decreased
hospital charges (adjusted mean difference = −$16,814,
p < 0.01), and decreased postoperative mortality (adjusted
OR = 0.42, p < 0.01). Using 1 : 1 propensity score matching,
patients who received EA (n = 1,070) had significantly
decreased postoperative LOS (11.0 days vs 12.1 days,
p = 0.01), lower hospital charges ($112,086 vs $128,939,
p < 0.01), and decreased postoperative mortality (1.5% vs
3.6%, p < 0.01) compared to matched controls without EA
(n = 1,070) (Table).
Conclusion: EA is associated with improved perioperative
outcomes and reduced hospital charges following pancreate-
ctomy. Additional studies are required to fully understand if
this relationship is causative.
LO-D.02 IMPACT OF MARGIN STATUS
ON SURVIVAL IN MAIN DUCT
INVOLVED INTRADUCTAL PAPILLARY
MUCINOUS NEOPLASM
M. T. Welsh1, A. M. Roch1, J. L. Cioffi1, J. J. Easler2,
J. M. DeWitt2, E. P. Ceppa1, M. G. House1,
N. J. Zyromski1, A. Nakeeb1, C. Schmidt1
1Department Of Surgery, Indiana University School Of
Medecine, Indianapolis, IN; 2Department Of Medicine,
Division Of Gastroenterology, Indiana University School
Of Medicine, Indianapolis, IN
Background: The natural history of Main Duct (MD)-
involved Intraductal Papillary Mucinous Neoplasm (IPMN)
is poorly understood. We examined the impact of pancreatic
margin status on recurrence and survival, and whether there
is benefit of total pancreatectomy (TP) over partial pancrea-
tectomy (PP).
Methods: A retrospective review of a prospectively main-
tained database of patients who underwent resection for
IPMN at a single academic center (2000–2013) was per-
formed.
Results: 152 patients with MD-involved IPMN were
included in this study. Of them, 15 underwent TP and 137 PP.
Median follow-up was 41 months. There was no difference in
surgical (postoperative complications, hospital stay) and
long-term outcomes (malignant recurrence, overall survival
OS and disease-free survival DFS) between TP and PP
groups. In patients who underwent PP, there was no differ-
ence in OS according to the presence of IPMN at margin (96
vs 123 months, p = 0.18). However, when present, degree of
IPMN dysplasia at the margin (low vs moderate vs high vs
invasive) impacted OS (84 vs 8 vs 13 vs 9 months, respec-
tively p = 0.002). In addition, topography of positive margin
in the ductal system (main vs branch vs mixed) impacted
DFS (19 vs 65 vs 34 months, respectively p = 0.009).
Conclusion: Positive margin status in main-duct involved
IPMN may have effects on patient survival. Involvement of
the main duct at the margin, and higher degrees of IPMN
dysplasia at the margin predict a worse survival. Total pan-
createctomy may need careful consideration in select patients
in these groups.
LO-D.03 INCREASED MORBIDITY AND
MORTALITY OF CONCOMITANT
COLECTOMY DURING
PANCREATICODUODENECTOMY:
A NSQIP PROPENSITY SCORE
MATCHED ANALYSIS
J. W. Harris, J. T. Martin, E. C. Maynard, P. C. McGrath,
C. D. Tzeng
University Of Kentucky, Lexington, KY
Introduction: Select patients with periampullary cancers
require concomitant colon resection (CR) during pancreati-
coduodenectomy (PD) for margin-negative resections. This
study analyzed the impact of concomitant CR on post-PD
major morbidity and mortality using a large national dataset.
Methods: National Surgical Quality Improvement Program
(NSQIP) patients undergoing PD for periampullary cancers
(with/without CR) from 2005–2012, were screened. A 4 : 1
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propensity score matched analysis was constructed to isolate
the impact of CR upon PD. Risk factors for 30-day major
morbidity and mortality were analyzed to determine the post-
operative sequelae of PD + CR.
Results: Of 10,965 PD and 159 PD + CR patients in total,
624 and 156, respectively, were selected for the 4 : 1 matched
analysis. PD + CR resulted in significantly higher major
morbidity and mortality (50.0% and 9.0%) vs. PD alone
(28.8% and 2.9%, respectively, p < 0.001). Multivariate
analysis identified the following risk factors for major mor-
bidity after PD: concomitant CR (OR-3.19, p < 0.001),
smoking history (OR-1.92, p = 0.005), lack of functional
independence (OR-3.29, p = 0.018), cardiac disease (OR-
2.39, p = 0.011), decreased albumin (per g/dL, OR-1.38,
p = 0.033), and longer operative time (vs. median time,
OR-1.56, p = 0.029). Independent predictors of mortality
included concomitant CR (OR-3.16, p = 0.010), ventilator
dependence (OR-13.87, p < 0.001), and septic shock (OR-
6.02, p < 0.001).
Conclusion: Contrary to previous single-institution studies,
this propensity score matched analysis using the NSQIP
dataset showed that adding CR to PD significantly increased
the magnitude of surgery and was an independent predictor
of both major morbidity and mortality. Using high-resolution
imaging, patients who may need PD + CR should be identi-
fied preoperatively, maximally optimized, and referred to
expert centers.
LO-D.04 LAPAROSCOPIC
PANCREATICODUODENECTOMY DOES
NOT COMPLETELY MITIGATE
INCREASED PERI-OPERATIVE RISKS IN
ELDERLY PATIENTS SEEN WITH OPEN
PANCREATICODUODENECTOMY
M. C. Tee, K. P. Croome, C. R. Shubert, M. B. Farnell,
M. J. Truty, F. G. Que, K. Reid-Lombardo, R. L. Smoot,
D. M. Nagorney, M. L. Kendrick
Mayo Clinic, Rochester, MN
Background: The effect of totally laparoscopic pancreati-
coduodenectomy (TLPD) in elderly patients has not been
evaluated. We hypothesize that increased peri-operative risks
associated with open pancreaticoduodenectomy (OPD) in
elderly patients may be mitigated with TLPD.
Methods: A review of prospectively collected data on all
pancreaticoduodenectomy (PD) was conducted from August
2008 to January 2014 (N = 756). Elderly patients (Age ≥70
years, N = 281) were compared to non-elderly patients (Age
<70 years, N = 475) with respect to risk-adjusted peri-
operative morbidity and mortality. Differences in outcomes
between TLPD (N = 106) versus OPD (N = 175) were evalu-
ated in the elderly subgroup in an intention-to-treat analysis.
Results: Elderly patients have increased risk of ICU admis-
sion, any cardiac event, and pneumonia following PD com-
pared to non-elderly patients. TLPD in elderly patients is
associated with decreased risk of surgical site infection (SSI)
and delayed gastric emptying (DGE) as well as decreased
estimated blood loss (EBL) and transfusion. Only factors that
were statistically significant on multivariate analysis are
reported in the results table. All other outcomes (pancreatic
fistula, hemorrhage, length of stay, etc.) were not statistically
significant on multivariate analysis.
Conclusions: Elderly patients undergoing TLPD experience
a similar risk of 90-day mortality, ICU admission, and car-
diopulmonary events compared to patients undergoing OPD.
TLPD does appear to offer benefits to the elderly with respect
to decreased EBL, DGE, and SSI.
LO-D.05 FACTORS INFLUENCING
FAILURE TO RESCUE AFTER
PANCREATICODUODENECTOMY:
A NSQIP PERSPECTIVE
P. Varley, A. Tsung
University Of Pittsburgh, PITTSBURGH, PA
Background: Previous studies have identified structural
factors that may impact the failure to rescue rate after
pancreaticoduodenectomy (PD). The goal of this study is to
identify patient-level factors associated with failure to rescue
in order to guide interventions that prevent progression to
mortality.
Methods: Patients undergoing PD as the primary procedure
were identified from the 2005–2012 National Surgical
Quality Improvement Project (NSQIP) Participant Data Use
(PUF) files. Since NSQIP only measures mortality for 30
days post-operatively, we treated failure to rescue as time to
event data and analyzed it using Cox proportional hazards
methods.
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Results: A total of 14,546 patients were available for analy-
sis. Of these, 1137 (7.8%) experienced only a minor compli-
cation while 5321 (36.6%) experienced at least one severe
complication. Failure to rescue rate was 0% vs. 5.9%, respec-
tively (p < 0.001). Failure to rescue rates were 1.2%, 4.2%
and 18.6% in patients experiencing a total of 1, 2 or 3+
serious complications (p < 0.001). Results from univariable
Cox regression were used to build a multivariable Cox model
which was refined by AIC criteria. Factors significantly influ-
encing failure to rescue after serious complication included
number of complications, resident participation, age,
reoperation, and dyspnea (Table 1).
Conclusions: Essentially all patients who experience post-
operative mortality after PD first had a serious complication.
Interestingly, our analysis shows that it is not the first post-
operative complication, but instead the accumulation of
multiple events that results in failure to rescue. Preventing
this progression should be the focus of future quality
improvement efforts.
LO-D.06 THE IMPACT OF RECENT
HOSPITALIZATION ON SURGICAL
SITE INFECTION FOLLOWING
PANCREATECTOMY
D. E. Sanford, R. C. Fields, W. G. Hawkins
Washington University In St. Louis, St. Louis, MO
Background: Surgical site infections (SSI) are a major
cause of increased morbidity and cost after pancreatectomy.
Patients undergoing pancreatectomy frequently have had
recent inpatient hospital admissions prior to their surgical
admission (recent presurgical admission, RPSA), which
could increase the risk of SSI. We sought to examine the
impact of RPSA on SSI following pancreatectomy.
Methods: We used the 2009–2011 Healthcare Cost Utiliza-
tion Project California State Inpatient Database. RPSA was
defined as hospital stays >48 hrs with a discharge date within
30 days prior to admission for pancreatectomy. We used
Chi-square tests, Student’s t tests, and multivariable logistic
regression.
Results: 3,376 patients underwent pancreatectomy, and 444
(13.2%) had RPSA. The most common RPSA diagnoses
were pancreatitis (n = 164, 36.9%) and biliary obstruction
(n = 255, 57.4%), and 235 (52.9%) underwent an endoscopic
procedure during RPSA. 180 (40.5%) RPSAs were to differ-
ent hospitals other than where patients’ pancreatectomy took
place. In univariate analysis, patients with RPSA had a sig-
nificantly higher rate of postoperative SSIs, and this was
associated with longer length of postoperative stay, higher
postoperative hospital costs, and increased postoperative
30-day readmission rates (Table). In Multivariate analysis,
RPSA was an independent predictor of postoperative SSI
(OR = 1.68, p = 0.013), and the risk of SSI increased with
increasing RPSA length of stay (OR = 1.07 per day,
p = 0.001).
Conclusions: RPSA is an important risk factor for SSI after
pancreatectomy. Many patients with RPSA are not admitted
preoperatively to the same hospital where pancreatectomy
occurs; in such circumstances, SSI rates may not be a sole
reflection of the care provided by operating hospitals.
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LO-D.07 PANCREATECTOMY WITH
VEIN RESECTION/RECONSTRUCTION:
TECHNIQUE MATTERS
M. M. Dua1, T. B. Tran1, J. Q. Klausner2, K. J. Hwa1,
G. A. Poultsides1, J. A. Norton1, B. C. Visser1
1Stanford University School Of Medicine, Stanford, CA;
2UCLA Medical Center, Los Angeles, CA
Introduction: A variety of techniques have been described
for portal vein (PV) and/or superior mesenteric vein (SMV)
resection/reconstruction during pancreatectomy. The ideal
strategy remains unclear.
Methods: Using a prospective database, we identified all
patients between 2005–2014 who underwent PV/SMV
resection/reconstruction during pancreatectomy (subtotal/
total/whipple) for all diagnoses. We reviewed the medical
records and imaging for operative details and outcomes, with
special emphasis on patency.
Results: Ninety patients underwent vein resection/
reconstruction with one of five techniques:1) longitudinal
venorrhaphy (n = 17, 19%); 2) transverse venorrhaphy
(n = 9, 10%); 3) primary end-to-end (n = 28, 31%); 4) patch
venoplasty (n = 17, 19%); and 5) interposition graft (n = 19,
21%). With median follow-up (last available imaging to
assess patency) of 282 dys, thrombosis was observed in
16/90 (18%). The rate of thrombosis varied according to
technique. All patients with primary end-to-end or transverse
venorrhaphy remained patent. Longitudinal venorrhaphy,
patch closure, and interposition graft were all associated with
significant rates of thrombosis (25%, 31%, 44%, respec-
tively, p < 0.01 vs no thrombosis). Comparing those
thrombosed to those that remained patent, there were no
differences with respect to pancreatectomy type, pre-
operative knowledge of vein involvement, and neoadjuvant
therapy. Patients with thrombosis had significantly longer
operative times (480 vs 401 min,p < 0.01) and increased
blood loss (1150 vs 600 mL,p < 0.05). Post-operative heparin
drip was used in only 7%. Prophylactic aspirin was used in
69% of the total cohort (66% of patent, 81% of thrombosed)
and showed no protective benefit.
Conclusions: Primary end-to-end and transverse venor-
rhaphy have better patency than the alternatives after
PV/SMV resection and should be the preferred techniques
for short (<3 cm reconstructions).
LO-D.09 DISTAL PANCREATECTOMY
WITH CELIAC AXIS RESECTION: WHAT
ARE THE ADDED RISKS?
J. D. Beane1, M. G. House1, S. C. Pitt3, E. M. Kilbane1,
B. L. Hall3, A. Parmar4, T. S. Riall4, H. A. Pitt2
1Indiana University School Of Medicine, Indianapolis, IN;
2Temple University School Of Medicine, Philadelphia, PA;
3Washington University School Of Medicine, St. Louis,
MO; 4University Of Texas Medical Branch, Galveston, TX
Background: Surgeons have become aggressive at operat-
ing on tumors of the body of the pancreas which require
resection of the celiac axis (Appleby procedure). Reported
series are small and not adequately controlled. The aim of
this analysis was to report a large series of Appleby pro-
cedures with a comparison group to determine the relative
risk.
Methods: Data were gathered through the American
College of Surgeons-National Surgical Quality Improvement
Program, Pancreatectomy Demonstration Project. Over 14
months, 822 patients underwent a distal pancreatectomy
(DP) at 43 institutions. Twenty of these patients (2.4%) also
underwent celiac axis resection (CAR). Appleby procedure
patients were then matched by age, gender, BMI, serum
albumin, ASA class, gland texture, duct size and pathology to
180 patients undergoing DP without CAR. Operative and
postoperative outcomes were compared by Fisher’s Exact
and Wilcoxon tests.
Results: The median age of the DP and DP + CAR patients
was 65 and 64 years, respectively. Most patients were female
(67 and 70%). The mean BMI of the two groups was
identical (27.1 kg/m2). The majority of patients had
adenocarcinomas (63 and 60%) or neuroendocrine tumors
(13 and 15%). Operating Room (OR) and postoperative out-
comes are presented in the table.
Conclusions: Distal pancreatectomy with celiac axis resec-
tion is associated with increased operative time, renal failure
and a 10% operative mortality. The decision to offer an
Appleby procedure should be made with full disclosure of
the increased risks.
LO-D.10 SURGICAL MANAGEMENT OF
CHRONIC PANCREATITIS: A THERAPY
IN DECLINE?
L. A. Bliss, C. J. Yang, M. Eskander, S. DeGeus,
M. P. Callery, T. S. Kent, A. J. Moser, S. D. Freedman,
J. F. Tseng
Beth Israel Deaconess Medical Center, Boston, MA
Background: Surgical intervention is uncommon in chronic
pancreatitis management. Literature largely describes single
institution or international experiences. This study describes
US-based chronic pancreatitis surgical management and its
impact on readmission rates.
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Methods: Retrospective analysis of chronic pancreatitis
patients in Healthcare Cost and Utilization Project Florida
State Inpatient Database 2007–2011 using revisit variables.
Patients with malignancy or congenital abnormalities
excluded. Surgical interventions and complications of
chronic pancreatitis identified using ICD-9 codes. Univariate
analysis of sex, Elixhauser score, race, insurance, complica-
tions, receipt of surgery by chi-square. Number of readmis-
sions, time to surgery by Wilcoxon rank sum. Multivariate
analysis of operative management by logistic regression.
Results: 21,448 chronic pancreatitis patients. 6.18% (1,325)
underwent surgery including 629 with drainage procedures,
275 with pancreatectomies, 735 with cholecystectomies.
Procedures decreased from 8.65% in 2007 to 3.10% in 2011
(p < 0.0001). 12.95% (2,778) developed pancreatitis-related
complications: pancreatic cysts or pseudocysts (4.40%), dia-
betes (10.02%). Pancreatic exocrine insufficiency in <11
patients. Median number of readmissions 1 (IQR 0–4) and 5
(IQR 2–9) among non-surgical and surgical patients, respec-
tively (p < 0.001). Median number of admissions prior to
pancreatectomy was 2 (IQR 1–4) and drainage procedure
was 2 (IQR 1–6). Predictors of surgical intervention dis-
played in table.
Conclusions: Chronic pancreatitis leads to numerous inpa-
tient readmissions and difficult to manage complications.
Surgical intervention occurs in a declining minority of cases.
Complicated patients are more likely to undergo surgery;
operative patients experience more admissions than
nonoperative patients. The complexities of chronic pancrea-
titis management warrant early multidisciplinary evaluation
and ongoing consideration of surgical and nonsurgical
options.
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LO-E.01 NEOADJUVANT
CHEMOTHERAPY DOES NOT IMPAIR
LIVER REGENERATION FOLLOWING
MAJOR HEPATECTOMY OR PORTAL
VEIN EMBOLIZATION FOR
COLORECTAL LIVER METASTASES
E. Simoneau1, N. Molla1, R. Alanazi2, J. Alshenaifi2,
M. Aljiffry3, A. Medkhaly2, L. Boucher1, P. Metrakos1,
M. Hassanain1,2
1Department Of Surgery, McGill University, Montreal, QC;
2Department Of Radiology, McGill University, Montreal,
QC; 3Department Of Surgery, College Of Medicine, King
Saud University, Riyadh, SA; 4Department Of Surgery,
Faculty Of Medicine, King Abdulaziz University, Jeddah,
SA; 5Department Of Oncology, McGill University,
Montreal, QC
Introduction: Treatment strategies for colorectal liver
metastasis (CRCLM) such as major hepatectomy and portal
vein embolization (PVE) rely on the regenerative capacity of
the liver. Neoadjuvant chemotherapy is most often used with
patients undergoing these procedures. We aimed to investi-
gate the effect of neoadjuvant chemotherapy on liver regen-
eration after PVE and after major hepatectomy.
Methods: All CRCLM patients undergoing PVE or major
resection (without PVE) with 3D liver volumetry measure-
ments were included. Liver regeneration (expressed as future
liver remnant (FLR) and percentage of liver regeneration(%
LR)), total liver volume (TLV) and clinical characteristics
were collected from our CRCLM database.
Results: Between 2003–2013, 226 patients were included
(85 major resections, 141 PVE). Mean age was 63 ± 12 years
old and median number of cycles was 6(5–8). In each group,
overall adequate regeneration was observed (+96.5% in FLR
(p < 0.001) post PVE and +45.8% in FLR (p < 0.001) post
resection). In the PVE group, chemotherapy variables did not
show significant association with the amount of liver regen-
eration (number of cycles (p = 0.435), timing (p = 0.563),
chemotherapy agent (p = 0.116)). Similarly in the major
hepatectomy group, neoadjuvant chemotherapy administra-
tion did not show a significant association with %LR
(p = 0.592) or with other treatment variables (number of
cycles, p = 0.114; agent, p = 0.061, timing, p = 0.126). In
both groups, the predicted FLR was inversely correlated with
the % in liver regeneration only (p < 0.001).
Conclusion: Neoadjuvant chemotherapy does not seem to
affect the liver regeneration. The predicted FLR only is
inversely correlating with the amount of LR occurring after
major resection or after PVE.
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